Caris proves scale with cash flow and new tests
- Q2 2026 revenue grew 45 percent year over year to $263.7 million.
- The company reported its fifth straight quarter of positive adjusted EBITDA and free cash flow.
- Caris Assure blood cases jumped 50 percent to 10,700 in the second quarter.
- Management raised full year revenue guidance to over $1 billion.
- The main risk is whether the company can build enough capacity for new product launches.
Scaling past breakeven
Caris is showing real scaling power. In Q2 2026, revenue rose 45 percent year over year to $263.7 million. More importantly, the company marked its fifth straight quarter of positive adjusted EBITDA and positive free cash flow. Management raised full year revenue guidance to over $1 billion.
The bull case rests on volume growth and new products. MI Profile tissue cases grew 13 percent to 48,300 in the quarter. Caris Assure blood testing cases surged 50 percent to 10,700. The company also launched two major tests, Caris Detect and ChromoSeq, expanding its market reach.
The bear case focuses on growing pains. Caris Detect demand could outpace the company roll out pace. Management warned that this capacity crunch requires major inventory spending and could cause back orders. The company must also secure payer coverage for its newest platforms to maintain its average selling price.
The next clear watch items are the scaling pace for Caris Detect, the rollout of the minimal residual disease program in late 2026, and potential approval in New York for blood testing.
Tests first, data second
Caris makes most of its money by selling molecular profiling services. These tests read cancer samples from tissue or blood to help doctors pick treatments. In Q2 2026, molecular profiling services produced $252.3 million of revenue.
The second business sells pharma research and development services. Drug companies use Caris data, testing, and bioinformatics to study cancer and improve drug programs. This part of the business contributed the rest of the quarter's revenue.
The model works best when test volumes rise and each test earns strong reimbursement. The major risk is execution. If new products face manufacturing limits or back orders, revenue growth could stall even with high demand.
A cancer testing stack
MI Profile
MI Profile is the tissue-based platform and generates most of the company revenue. Q2 2026 cases reached 48,300.
Caris Assure
Caris Assure is the blood-based profiling platform. Q2 2026 cases jumped 50 percent year over year to 10,700.
Caris Detect
Launched in June 2026, this multi-cancer early detection assay covers 58 cancer types. It is a major catalyst but faces near-term capacity limits.
ChromoSeq
Launched in April 2026, this therapy selection assay features whole genome and whole transcriptome technology. It already has initial payer coverage.
Precision Whole Genome Platform
Caris expects to launch whole genome sequencing solutions in 2026. This could broaden the test menu, but adoption and payment still need to be proven.
Biopharma R&D services
Caris works with drug companies on testing, data, and discovery projects. This smaller business makes the data platform more valuable.
Mostly clinical testing
The mix is from Q2 2026 revenue. Molecular profiling is the clear revenue base, so any reimbursement or capacity change in that line matters a lot.
What could break
Capacity constraints
High impact · Medium oddsManagement noted that near-term demand for the newly launched Caris Detect could outstrip the rollout pace. This creates a risk of back orders and requires heavy inventory spending before revenue is realized.
Reimbursement pressure
High impact · Medium oddsHigher reimbursement rates have helped lift the average selling price for older tests. If payers cut rates or limit coverage for new platforms like ChromoSeq, growth could slow even if test volume keeps rising.
Caris Assure adoption stalls
High impact · Medium oddsCaris Assure is a key growth product because it uses blood instead of tissue. Q2 2026 case volume rose to 10,700, but it still needs broader use by doctors and payers. If that curve flattens, a major growth engine stalls.
Debt-funded expansion misfires
Medium impact · Low oddsCaris has access to up to $1.2 billion in debt capacity, with $400.0 million initially funded. That gives it room to expand or buy assets. It also raises the cost of a bad deal if growth does not follow.
In one breath
What does Caris Life Sciences do?
Caris sells cancer molecular profiling tests. These tests study tumor tissue or blood so doctors can better match patients with treatments.
How does Caris make money?
Most revenue comes from molecular profiling services sold for clinical use. A smaller part comes from pharma research and development services, where drug companies use Caris testing, data, and bioinformatics.
Is Caris profitable?
Yes, on a cash basis. The company reported its fifth consecutive quarter of positive adjusted EBITDA and positive free cash flow in Q2 2026.
What is the biggest catalyst for CAI stock?
The clearest near-term catalysts are the scaling of newly launched Caris Detect and ChromoSeq, continued Caris Assure volume growth, and a planned minimal residual disease program.
